Clinical Trial

Vunakizumab in Adults with Spondyloarthritis

Study acronym: V SPA
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2025 (before its estimated January 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective, single-arm, multicenter study is aimed to explore the efficacy and safety of Vunakizumab in adults with spondyloarthritis. The primary endpoint is the proportion of adults with spondyloarthritis achieving ankylosing spondylitis assessment score (ASAS) 40 at week 16 in the treatment of Vunakizumab.
Trial Details
NCT Number NCT06770088
Lead Sponsor Sun Yat-sen University
Conditions Spondyloarthritis (SpA)
Enrollment 880 participants
Start Date 2025-01-10
Primary Completion 2026-01-10 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-13